As the stock market is challenging all-time highs around a holiday week, investors have to be considering how to position their portfolios and assets for 2014 and beyond. 24/7 Wall St. has been issuing value outlooks and sector outlooks for 2014 to see where the best spots are ahead.
It turns out that there may be some incredible upside left in selective autos and biotechs. Some financial stocks may offer upside, and there is still some value in oil and gas. We will be following up with more 2014 outlook pieces in December.
The best carmaker for 2014 appears to be General Motors Co. (NYSE: GM). With the government out of the shares, its stock muted since its re-IPO and an attractive earnings multiple of only eight times expected earnings in 2014, GM was the winner against peers. By the way, analysts see more than 25% gains on average in GM’s share price over the next year.
Regions Financial Corp. (NYSE: RF) is a top pick at Jefferies for 2014 in its most recent sector and themes trend report�for the year ahead. The super-regional bank is the 15th largest one in the United States, and its net interest margin keeps moving up. Regions’ consensus analyst price target is posted up about $1 from current prices, implying gains of 10% over the coming year.
Top 5 Gas Stocks To Invest In 2015: Brazil Gold Corp (BRZG)
Brazil Gold Corp. incorporated on June 17, 2004, is engaged in reviewing mineral exploration. The Company has a Letter of Intent with Mineracao Rio De Padreas Ltda to acquire up to 100% of Mineracao�� interests in the Luziania Gold Project located in Goias State, Brazil. The Luziania Gold Project (LGP) is located about 50 kilometers southwest of Brasilia and 10 kilometers from the City of Luziania. LGP carries mining permits, environmental impact studies and ore recovery analyses. Effective July 30, 2013, Brazil Gold Corp acquired a 20% interest in FAL Minerals LLC, a gold mining company.
The Company is focused on reviewing exploration and other opportunities with the objective of bringing revenue to the Company. As of June 30, 2011, the Company was focused on evaluating possible new ventures and acquisitions. As of June 30, 2011, the Company had not generated any revenues from its operations.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks Brazil Gold Corp (OTCMKTS: BRZG) and Trulan Resources (OTCMKTS: TRLR) were either active on the charts last week (in the case of the former) or recently the subject of paid promotions (in the case of the latter). However, mining is not exactly an easy business for a small and usually undercapitalized small cap mining stock given the amount it can cost to get a mine up and running. On the other hand, they could always be sitting on the next mother lode just waiting to come out of the ground. With that in mind, here is a quick reality check about these two small cap mining stocks:
Top 5 Regional Bank Stocks To Own For 2014: Pegasystems Inc.(PEGA)
Pegasystems Inc. develops, markets, licenses, and supports software to automate business processes primarily in the United States, the United Kingdom, and rest of Europe. The company offers PegaRULES Process Commander, which provides a platform to build, deploy, and change enterprise applications; purpose or industry-specific solution frameworks that enable organizations to implement new customer-facing practices and processes, and provide customized or specialized processing to meet the needs of different customers, departments, geographies, or regulatory requirements; and Pega customer relationship management software to automate customer service inquiries and marketing, and apply analytics to predict and adapt customer service processes. It also offers Pega decision management products, which include Pega Decision Strategy Manager and Next-Best-Action Advisor that support decision-making for offer management, risk, and other marketing and customer management solutions; and Pega Cloud, which enables customers to create and/or run Pega applications using an Internet-based infrastructure. In addition, the company provides implementation, consulting, training, and technical support services to its customers. The company markets its software and services primarily through its direct sales force to financial services organizations, healthcare organizations, insurance companies, communications and media organizations, and government agencies. Pegasystems Inc. was founded in 1983 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Patricio Kehoe]
The firm is currently Zacks Rank # 3 - Hold, and it also has a longer-term recommendation of ��utperfom�� For investors looking for a Zacks Rank # 1 ��Strong Buy, Dealertrack Technologies Inc (TRAK), Open Text Corporation (OTEX), Pegasystems Inc. (PEGA) Solera Holdings (SLH) or Ultimate Software Group Inc. (ULTI) could be the options.
- [By Garrett Cook]
Technology shares rose by just 0.05 percent on Wednesday. Top losers in the sector included Pegasystems (NASDAQ: PEGA), down 13.4 percent, and HomeAway (NASDAQ: AWAY), off 11 percent.
Top 5 Regional Bank Stocks To Own For 2014: TAM S.A.(TAM)
TAM S.A. provides passengers and cargo air transportation services in Brazil and internationally. It also engages in the aircraft acquisition, financing, and debt issuance activities. In addition, the company offers travel and tourism agency services, as well as is involved in the development and management of customer loyalty programs. It operates a fleet of approximately 156 aircrafts. The company was founded in 1961 and is based in S� Paulo, Brazil. TAM S.A. is a subsidiary of TAM-Empreendimentos e Participa珲es S.A.
Advisors' Opinion:- [By Jeremy Bowman]
What: Shares of Taminco (NYSE: TAM) were looking brighter today, gaining as much 13% after a promising quarterly earnings report, its first as a public company.
- [By Jake L'Ecuyer]
Taminco (NYSE: TAM) shares tumbled 7.53 percent to $19.30 after the company priced secondary offering of 10 million shares of common stock at $20 per share.
Top 5 Regional Bank Stocks To Own For 2014: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Advisors' Opinion:- [By Lee Jackson]
Amgen Inc. (NASDAQ: AMGN) is a company doing the acquiring. The company recently completed a $10.4 billion purchase of Onyx Pharmaceuticals Inc. (NASDAQ: ONYX) to add its cancer drug Kyprolis to its already sprawling portfolio. UBS has a $124 price target on the stock. The consensus target is at $123. Investors are paid a 1.7% dividend.
- [By Ben Levisohn]
Celgene’s drop has, in fact, been modest. Its shares have fallen 0.5% to $85.28 at 10:26 a.m., while Amgen (AMGN) has dipped 0.4% to $119.45, Biogen Idec (BIIB) has declined 0.6% to $315.58 and the iShares Nasdaq Biotechnology ETF (IBB) is off 0.6% at $252.28.
- [By Keith Speights]
Nothing like being wanted
Onyx Pharmaceuticals (NASDAQ: ONXX ) experienced the thrill of being wanted this week. Shares soared nearly 57% this week after word leaked last weekend that Amgen (NASDAQ: AMGN ) offered to buy the company for $120 per share. - [By Ben Levisohn]
Shares of Amgen (AMGN) are sliding in after-hours trading after the biotech giant reported weaker than forecast earnings.
Amgen reported an adjusted profit of $1.87 a share, below forecasts for $1.94, on sales of $4.5 billion, missing the Street consensus for $4.76 billion. Amgen did, however, reiterate its full year forecast for earnings between $7.90 and $8.20. Analysts expect $8.16.
Shares of Amgen�rose 2% to $119.30 today but have fallen 2.7% to $116.07 at 4:23 p.m. in after-hours trading.
No comments:
Post a Comment